Our purpose

Relieving viral vector manufacturing bottlenecks

Vision & Mission

Our ultimate goal of Exothera is making life-changing therapies available for all. To achieve this, our teams’ mission is to design and deliver bespoke bioproduction journeys for viral vector therapy innovators to achieve successful market entry. 

Our philosophy

The challenges of taking a viral vector-based therapy from pre-clinical development to the production of the first batch of GMP products for clinical studies can be a daunting task. The biggest challenges are a lack of access to both process development expertise and a GMP manufacturing facility with the capacity and knowledge to quickly and cost-effectively produce enough quality product for clinical trials and beyond.

Exothera is your trusted CDMO partner who can help to rapidly and efficiently complete the process development and manufacture of just the right quantity of therapeutic to get through the next stage of clinical trials successfully, to secure further funding, and to move the therapy closer to market.

OUR HISTORY

Where we come from

1990

Belgian and Walloon ecosystem

Since the 90s, Wallonia has been a bio-manufacturing hub with the creation of several international companies.

2013

Launch of Univercells

In 2013, Univercells was created with the ambition to make biologics available and affordable to all.

2020

Creation of Exothera to relieve viral vector manufacturing bottlenecks

In March 2020, Univercells launched Exothera to support cell & gene therapy developers with process development and production of viral vectors.

With 15,000m² GMP capabilities Exothera is willing to relieve viral vector manufacturing bottlenecks.

The viral vector-based therapy market is expanding rapidly and Exothera will help to alleviate the three most critical challenges manufacturers face:

 

  • Lack of expertise: there is a lack of C&GT specific expertise in this field; the CMC and manufacturing processes are highly specific. 
  • Capacity storage: the number of specialized manufacturers is limited worldwide; manufacturing slot lead time of 12-18 months. 
  • High costs: cell & gene therapies are too expensive to be widely adopted; products priced between $85,000 and $2,100,000 for one patient! 

OUR FUTURE

Starting today

2020

Establish a full-service viral vector CDMO facility in the heart of Europe, accommodating sizeable production capabilities from R&D to clinical trial phases.

2021

Achieve operational GMP clinical manufacturing in a state-of-the-art facility in Jumet, Belgium.

2022

Extension to commercial manufacturing and build-out of capabilities around the world.

Vision & Mission

Our ultimate goal of Exothera is making life-changing therapies available for all. To achieve this, our teams’ mission is to design and deliver bespoke bioproduction journeys for cell & gene therapy innovators to achieve successful market entry. 

Our philosophy

The challenges of taking a viral vector-based therapy from pre-clinical development to the production of the first batch of GMP products for clinical studies can be a daunting task. The biggest challenges are a lack of access to both process development expertise and a GMP manufacturing facility with the capacity and knowledge to quickly and cost-effectively produce enough quality product for clinical trials and beyond.

Exothera is your trusted CDMO partner who can help to rapidly and efficiently complete the process development and manufacture of just the right quantity of therapeutic to get through the next stage of clinical trials successfully, to secure further funding, and to move the therapy closer to market.

OUR HISTORY

Where we come from

1990

Belgian and Walloon ecosystem

Since the 90s, Wallonia has been a bio-manufacturing hub with the creation of several international companies.

2013

Launch of Univercells

In 2013, Univercells was created with the ambition to make biologics available and affordable to all.

2020

Creation of Exothera to relieve viral vector manufacturing bottlenecks

In March 2020, Univercells launched Exothera to support cell & gene therapy developers with process development and production of viral vectors.

With 15,000m² GMP capabilities Exothera is willing to relieve viral vector manufacturing bottlenecks.

The viral vector-based therapy market is expanding rapidly and Exothera will help to alleviate the three most critical challenges manufacturers face:

 

  • Lack of expertise: there is a lack of C&GT specific expertise in this field; the CMC and manufacturing processes are highly specific. 
  • Capacity storage: the number of specialized manufacturers is limited worldwide; manufacturing slot lead time of 12-18 months. 
  • High costs: cell & gene therapies are too expensive to be widely adopted; products priced between $85,000 and $2,100,000 for one patient! 

OUR FUTURE

Starting today

2020

Establish a full-service viral vector CDMO facility in the heart of Europe, accommodating sizeable production capabilities from R&D to clinical trial phases.

2021

Achieve operational GMP clinical manufacturing in a state-of-the-art facility in Jumet, Belgium.

2022

Extension to commercial manufacturing and build-out of capabilities around the world.